This indefinite delivery contract was awarded by the Department of Veterans Affairs National Acquisition Center to Novo Nordisk Inc. for the supply of once-weekly Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, including semaglutide (Ozempic) and dulaglutide. The single-award IDV has a total ceiling value of $598,189,800 and a period of performance from November 2, 2020 through November 1, 2025, with four one-year option periods.
The contract aims to provide an uninterrupted, cost-effective supply of these critical medications to the VA, Bureau of Prisons, and Indian Health Service. Task orders under the IDV facilitate distribution to VA hospitals and clinics, the Department of Defense, and other federal customers. Novo Nordisk is a global pharmaceutical company that specializes in diabetes care solutions, including injectable drugs like semaglutide for type 2 diabetes management. This IDV leverages Novo Nordisk's manufacturing capabilities to support federal health programs' needs for these specialized GLP-1 agonist medications.
Generated 12/22/24, 12:03 AM